UltraGreen.ai gets regulatory approval for its products in Malaysia and the Philippines

[SINGAPORE] Surgical technology firm UltraGreen.ai has secured dual market regulatory approvals for two of its products less than a month since its trading debut on the Singapore Exchange.

It clinched approvals for Verdye, a fluorescence dye used in fluorescence-guided surgery, in the Philippines. It also secured approval for IC-Flow Imaging System V2 – a medical infrared camera system that captures fluorescent images in surgical procedures, in Malaysia.

On Tuesday (Dec 30), the company said that the approvals mark an “important step” in its strategic expansion across South-east Asia, where healthcare demand is growing.

This comes as UltraGreen.ai aims to expand the use of fluorescence-guided surgery – which has become an increasingly important tool across surgical procedures and specialties – in the region.

Declan Cassells, chief operating officer of UltraGreen.ai, said that the approvals will facilitate the company’s delivery of surgical technologies to healthcare systems across the South-east Asia.

“With these approvals in place, UltraGreen.ai and its local partners can now actively support education, training and broader clinical adoption of indocyanine green-based techniques among surgeons in both markets,” the company said.

SEE ALSO

UltraGreen.ai closes up 4.8% on SGX trading debut in largest non-Reit IPO since 2017

UOBKH initiates coverage on UltraGreen.ai with ‘buy’ on optimistic growth outlook

Will UltraGreen.ai be able to shine in a market dominated by big, dividend-paying companies?

Beyond regulatory approvals, the company said that it is growing its footprint in the region via clinical partnerships and market access initiatives.

Quek Mei Ling, chief business officer for Asia-Pacific at UltraGreen.ai, noted that the approvals come as South-east Asia is experiencing a rise in surgical procedures across oncology, colorectal and reconstructive care.